Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

Psyence BioMed (Nasdaq: PBM) has formed Texas Ibogaine Research Corporation, a Texas-based entity created to coordinate its U.S. ibogaine development across pharmaceutical-grade supply, regulatory engagement and potential clinical work. TIRC is positioned to hold U.S. rights to PsyLabs' pharmaceutical-grade ibogaine, but only subject to completion of definitive licensing arrangements; Psyence BioMed already holds an ownership interest in PsyLabs.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.